You are here

Trump Aims to Take Immediate $1.2 Billion Bite Out of NIH Budget

Biomedical research goes under the knife

President Trump’s administration has proposed cutting $1.23 billion this fiscal year from research funded by the National Institutes of Health (NIH), according to a report from Bloomberg Politics. The reduction is part of $18 billion in cuts that the administration wants in fiscal 2017, which ends in October.

Most of the proposed reductions at the NIH would come from research grants, with $50 million taken from a program meant to support biomedical research in states that typically get less agency money. It’s up to Congress to set spending levels, however, and many of the more-drastic measures proposed by the Trump administration are unlikely to become law, the Bloomberg article notes.

Asked if there was a chance the cuts would be implemented, Missouri Senator Roy Blunt, a Republican who serves on the Appropriations Committee, said “No. No.”

A worldwide initiative to help people with human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS), known as PEPFAR, would be slashed by almost $300 million under the plan. States would also face a $50 million cut that would target “less-effective HIV research and prevention activities.”

Other proposed health cuts for the current year include $40 million from staffing funds at the FDA, achieved in part with “slower than anticipated hiring.”

Trump has already proposed cutting biomedical research at the NIH by $5.8 billion next fiscal year, or approximately 18% below 2017 levels.

Source: Bloomberg; March 28, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks